Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.

Histopathology - 1 Oct 2022

Fitzpatrick Megan J, Boiocchi Leonardo, Fathi Amir T, Brunner Andrew M, Hasserjian Robert P, Nardi Valentina

Abstract excerpt

AIMS: TP53-mutated acute myeloid leukaemia (AML) is associated with an adverse prognosis and poor response to traditional chemotherapy regimens. Next-generation sequencing (NGS) is considered the gold standard method to determine TP53-mutational status; however, molecular assays are costly and time-consuming. In contrast, immunohistochemistry (IHC) can be performed within 1 day of biopsy. We sought to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 35869818
DOI: 10.1111/his.14726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.PMID 35869818Read ↗

Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistrySemantic proximity Read ↗

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.Semantic proximity Read ↗

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.Semantic proximity Read ↗

Overall survival in TP53-mutated AML and MDS.Semantic proximity Read ↗

Correlation of NPM1 immunohistochemistry with mutation subtypes, clinicopathologic variables and molecular testing in AML with NPM1 mutation.Semantic proximity Read ↗

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting.Semantic proximity Read ↗

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Semantic proximity Read ↗

TP53 in MDS and AML: Biological and clinical advances.Semantic proximity Read ↗

<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesSemantic proximity Read ↗

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemiaSemantic proximity Read ↗

Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in lung adenocarcinoma (LUAD).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.